'Progressive Approval' Coming? US FDA Considers Accelerated Approval Without Surrogates
Commissioner Gottlieb tells Congress that concept could be used for some clinical endpoints when a large benefit is seen in a small trial, which could benefit rare disease drug development.
You may also be interested in...
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
The data may be different, but US FDA will consider real-world evidence to add a tissue-agnostic indication, as well as take it away.
FDA’s decision to restrict use based on the level of PD-L1 expression shows how confirmatory trials for accelerated approval can help to inform and adapt labeling.